Please assess the completion status of the following clinical trial:

Trial Title: Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female pediatric patients of all ethnicities (age newborn to 6 years) with known or suspected CHD with inconclusive echocardiographic exams and are referred for cardiovascular MRI for further evaluation of cardiac anatomy and function.~* Written informed consent obtained from subject's legal representative/guardian(s) and ability for subject to comply with the requirements of the study~Exclusion Criteria:~* Standard clinical contraindications to MRI, including subjects with cochlear implants and implanted cardiac devices~* Subjects with past or current diagnosis of iron overload due to hereditary hemochromatosis or other causes (for subjects receiving Feraheme injection only).~* Subjects with known hypersensitivity or allergy to iron oxide particles.~* Subjects with renal insufficiency defined as estimated glomerular filtration rate (eGFR) \< 40 mL/min/1.73m2 (for subjects receiving Ablavar injection only).~* Subjects who are critically ill at the time of MRI and for whom the period of general anesthesia and separation from the critical care nursery or intensive care unit poses added risk as deemed by referring cardiologists, cardiac surgeons or the managing radiologist (for Part II only).~* Other medical conditions, in the judgment of the clinician investigator, that would increase the risks to the child related to participation in the study.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol (Type: ACTIVE_COMPARATOR): Ferumoxytol, 4mg/kg of body weight, one time infusion of several minutes
- gadofosveset (Type: ACTIVE_COMPARATOR): gadofosveset, 0.03mmol/kg, one time bolus injection

Based on this trial design, predict the completion outcome and termination type (if applicable).